2018 NCCN Nursing Program: Advancing Oncology Nursing

Orlando, FL US
March 21, 2018

The NCCN 2018 Oncology Nursing Program at the NCCN 23rd Annual Conference will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting. The program agenda includes the following topics: Improving Quality of Care for Lesbian, Gay, Bisexual, and Transgender (LGBT) Patients; Substance Use in Patients with Cancer; Optimizing Oral Therapy in Kidney Cancer; Management of Cardiovascular Toxicities Associated with TKI Therapy; Management of Hypersensitivity Reactions to Systemic Therapy; Safe Handling of Hazardous Drugs; and Implementing a CAR T-Cell Therapy Program.



Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

Improving Quality of Care for Lesbian, Gay, Bisexual, and Transgender (LGBT) Patients
•    Describe how rates of cancer screening uptake, incidence, and treatment outcomes in the LGBT populations compare to the general population and what may account for differences between these groups.
•    Discuss common disparities LGBT individuals experience during their cancer care.
•    Identify strategies to improve the quality of cancer care provided to LGBT patients and to provide welcoming and inclusive practice environments.

Substance Use in Patients with Cancer
•    Understand risk factors for substance use in patients with cancer.
•    Discuss the potential implications of substance use among patients with cancer.
•    Identify tools that can be used to screen for or monitor substance misuse/abuse.

Optimizing Oral Therapy in Kidney Cancer
•    Compare the current understanding on the benefits of targeted therapies in the treatment of first line, second line, and subsequent lines of therapy renal cell carcinoma.
•    Learn the adverse events associated with the oral therapies available for advanced RCC and strategies to manage them.
•    Provide education to patients on safe and effective administration of oral therapy emphasizing the importance of adherence to therapy.

Management of Cardiovascular Toxicities Associated with TKI Therapy
•    Describe the different types of cardiovascular toxicities associated with TKI therapy.
•    Discuss the current strategies for monitoring cardiac function and management of cardiovascular toxicities of TKI therapy.
•    Develop an individualized treatment plan based on the toxicity profile of TKI therapy, cardiovascular risk assessment and early identification of signs and symptoms.

Management of Hypersensitivity Reactions to Systemic Therapy
•    Discuss the pathophysiology of the different types of infusion-related HSR to chemotherapeutic agents and MABs.
•    Review the strategies used for the prevention and treatment of infusion-related HSR to systemic therapy.
•    Develop an evidence-based treatment plan for the management of infusion-related HSR in patients receiving systemic therapy.  

Safe Handling of Hazardous Drugs
•    Explain the health risks associated with occupational exposure to hazardous drugs or drug waste.
•    Understand standards for safe handling of hazardous drugs by oncology nurses, as specified in USP <800>.
•    Identify barriers to compliance with recommendations for safe handling of hazardous drugs in the oncology setting.

Implementing a CAR T-Cell Therapy Program
•    Summarize key symptoms associated with CAR T-cell therapy.
•    Outline current therapeutic strategies used as supportive care measures for adverse events stemming from CAR T-cell therapy.
•    Identify mechanisms that can be utilized to implement a CAR T-cell therapy program.

Additional information

Supported by educational grants from:

  • Celgene Corporation
  • Novartis
  • Pfizer

Supported by an independent educational grant from Incyte.
Supported by a medical education grant from Exelixis, Inc.
Supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs

Course summary
Available credit: 
  • 5.25 ANCC contact hours
  • 5.25 Participation
Course opens: 
Course expires: 
Event starts: 
03/21/2018 - 8:00am EDT
Event ends: 
03/21/2018 - 3:00pm EDT
Rosen Shingle Creek
9939 Universal Boulevard
Orlando, FL 32819
United States

All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 5.25 contact hours.

Available Credit

  • 5.25 ANCC contact hours
  • 5.25 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing